figures_charts

Shares plunge at Sarepta after negative FDA review on muscle disorder drug

pharmafile | April 21, 2016 | News story | Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta 

Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the FDA to its muscle disorder drug, eteplirsen.

Officials from the FDA reiterated their concerns over the drug intended to treat a subset of patients with Duchenne muscular dystrophy (DMD). Sarepta had been asked to provide additional information to the FDA and, although shares rose on the news of its further consideration, they have plummeted rapidly on this latest news from the FDA.

In their determination, staff at the FDA wrote: “The data overall did not provide statistical evidence to support the efficacy in subjects who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.” In short, they concluded that the drug was not as efficacious as it should be to warrant approval.

At the time of writing, Sarepta’s share price had fallen 38%.

Sean Murray

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

GSK’s meningococcal vaccine candidate accepted for FDA review

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan …

Latest content